Company logo

DYN - Dyne Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Waltham, United States
Type: Equity

DYN price evolution
DYN
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $123.94 $132.6 $169.93 $183.44
Short term investments $1.47 $27.54 $40.13 $57.1
Net receivables
Inventory
Total current assets $129.38 $168.22 $213.17 $249.21
Long term investments
Property, plant & equipment $33.39 $34.7 $35.92 $37.11
Goodwill & intangible assets
Total noncurrent assets $35.71 $37.03 $38.25 $39.43
Total investments $1.47 $27.54 $40.13 $57.1
Total assets $165.08 $205.24 $251.42 $288.64
Current liabilities
Accounts payable $22.94 $3.55 $2.72 $8.77
Deferred revenue
Short long term debt $4.72 $4.71 $4.71 $4.64
Total current liabilities $51.09 $29.69 $20.22 $21.59
Long term debt $22.7 $23.51 $24.32 $25.12
Total noncurrent liabilities $22.7 $23.51 $24.32 $25.12
Total debt $27.41 $28.23 $29.04 $29.76
Total liabilities $73.79 $53.21 $44.54 $46.71
Shareholders' equity
Retained earnings -$632.51 -$565.87 -$505.66 -$440.76
Other shareholder equity -$0.01 -$0.06 -$0.2
Total shareholder equity $91.29 $152.04 $206.88 $241.94
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $123.94 $174.47 $200.82 $300.85
Short term investments $1.47 $83.86 $175.75 $44.46
Net receivables
Inventory
Total current assets $129.38 $265.59 $382.39 $349.09
Long term investments
Property, plant & equipment $33.39 $38.41 $40.96 $1.95
Goodwill & intangible assets
Total noncurrent assets $35.71 $40.73 $43.27 $4.25
Total investments $1.47 $83.86 $175.75 $44.46
Total assets $165.08 $306.32 $425.66 $353.33
Current liabilities
Accounts payable $22.94 $5.26 $4.03 $3.44
Deferred revenue
Short long term debt $4.72 $4.61 $3.89
Total current liabilities $51.09 $28.09 $28.72 $10.97
Long term debt $22.7 $25.87 $28.74
Total noncurrent liabilities $22.7 $25.87 $28.74
Total debt $27.41 $30.48 $32.64
Total liabilities $73.79 $53.96 $57.47 $10.97
Shareholders' equity
Retained earnings -$632.51 -$396.57 -$228.47 -$79.18
Other shareholder equity -$0.57 -$0.27 -$0.03
Total shareholder equity $91.29 $252.36 $368.2 $342.37
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $58.84 $55.25 $59.13 $37.54
Selling, general & administrative $8.84 $7.02 $7.61 $7.93
Total operating expenses $67.69 $62.27 $66.74 $45.46
Operating income -$67.69 -$62.27 -$66.74 -$45.46
Income from continuing operations
EBIT -$66.64 -$60.21 -$64.9 -$44.19
Income tax expense
Interest expense
Net income
Net income -$66.64 -$60.21 -$64.9 -$44.19
Income (for common shares) -$66.64 -$60.21 -$64.9 -$44.19
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $210.76 $142.76 $121.31 $45.2
Selling, general & administrative $31.4 $28.2 $28.72 $13.45
Total operating expenses $242.16 $170.96 $150.03 $58.65
Operating income -$242.16 -$170.96 -$150.03 -$58.65
Income from continuing operations
EBIT -$235.94 -$168.1 -$149.29 -$59.04
Income tax expense
Interest expense $0.4
Net income
Net income -$235.94 -$168.1 -$149.29 -$59.44
Income (for common shares) -$235.94 -$168.1 -$149.29 -$59.44
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$66.64 -$60.21 -$64.9 -$44.19
Operating activities
Depreciation $0.57 $0.6 $0.67 $0.62
Business acquisitions & disposals
Stock-based compensation $5.73 $4.88 $4.75 $4.62
Total cash flows from operations -$35.01 -$50.6 -$55.64 -$46.91
Investing activities
Capital expenditures -$0.08 -$0.17 -$0.25 -$0.23
Investments $26.28 $12.99 $17.48 $27.29
Total cash flows from investing $26.2 $12.82 $17.23 $27.06
Financing activities
Dividends paid
Sale and purchase of stock $0.15 $0.45 $24.91 $28.82
Net borrowings
Total cash flows from financing $0.15 $0.45 $24.91 $28.82
Effect of exchange rate
Change in cash and equivalents -$8.66 -$37.33 -$13.5 $8.97
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$235.94 -$168.1 -$149.29 -$59.44
Operating activities
Depreciation $2.46 $3.35 $0.34 $0.7
Business acquisitions & disposals
Stock-based compensation $19.97 $15.18 $17.54 $6.59
Total cash flows from operations -$188.16 -$153.65 -$119.56 -$46.51
Investing activities
Capital expenditures -$0.73 -$3.07 -$3.62 -$1.16
Investments $84.04 $90.27 -$134.27 -$44.5
Total cash flows from investing $83.31 $87.2 -$137.89 -$45.66
Financing activities
Dividends paid
Sale and purchase of stock $54.32 $37.39 $157.82 $246.42
Net borrowings -$0.06
Total cash flows from financing $54.32 $37.39 $157.82 $380.69
Effect of exchange rate
Change in cash and equivalents -$50.52 -$29.05 -$99.63 $288.52
Fundamentals
Market cap $1.75B
Enterprise value $1.65B
Shares outstanding 61.47M
Revenue $0.00
EBITDA -$233.48M
EBIT -$235.94M
Net Income -$235.94M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -7.40
EV/Sales N/A
EV/EBITDA -7.06
EV/EBIT -6.99
P/S ratio N/A
P/B ratio 19.12
Book/Share 1.49
Cash/Share 2.02
EPS -$3.84
ROA -103.66%
ROE -136.35%
Debt/Equity 0.81
Net debt/EBITDA 0.21
Current ratio 2.53
Quick ratio 2.53